Smith & Nephew positions itself for the post-2010 generation of tissue & bone repair products
This article was originally published in Clinica
Executive Summary
Smith & Nephew's splitting of its orthopaedics division into recon and trauma in early 2006 was the latest major restructuring step for a group that has undergone much change since CEO Sir Christopher O'Donnell took charge nine years ago. In an interview with Ashley Yeo at the group's headquarters on London's Strand, he explained why this was necessary and how the group is positioning itself to be a major player in next-generation products
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.